NewAmsterdam Pharma (NAMS) Amortization of Deferred Charges (2025 - 2026)
NewAmsterdam Pharma (NAMS) posted Amortization of Deferred Charges of $10000.0 for Q1 2026, up 141.67% sequentially from -$24000.0 in Q4 2025, and up 101.95% YoY from $4951.7 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Amortization of Deferred Charges for 2 years, with the latest figure at $10000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 101.95% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$882000.0 (changed N/A YoY) and the FY2025 annual result came in at -$1.4 million, down 518.94% from the prior year.
- Amortization of Deferred Charges climbed to $10000.0 in Q1 2026 per NAMS's latest filing, from -$24000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $10000.0 in Q1 2026 and troughed at -$513000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | -24,000.00 |
| Sep 30, 2025 | -396,000.00 |
| Jun 30, 2025 | -472,000.00 |
| Mar 31, 2025 | -513,000.00 |